Changjiang Life Science & Technology (00775) signs abandonment agreement with DWTX.

Wisdom Financial News App News, Yangtze Life Science and Technology (00775) announced that, as disclosed in the first announcement, in accordance with the Share Purchase Agreement, the Buyer (a wholly-owned subsidiary of the Company) issued the Buyer with ordinary shares as payment shares and the Buyer, Dogwood Therapeutics, Inc. (Nasdaq: DWTX) issued the Buyer with preferred shares as payment shares as consideration for selling 100% of the equity of the target company (Pharmagesic (Holdings) Inc), and the Buyer's preferred shares as payment shares provide the Seller with cash settlement rights and repurchase rights. On September 26, 2025, the Seller and the Buyer entered into a Waiver Agreement, wherein both parties agreed to waive the cash settlement rights and repurchase rights for certain Buyer's preferred shares as payment shares.